Stock Groups

Asian firm Beximco to sell generic version of Merck COVID-19 pill -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021.

(Reuters) – Bangladesh’s Beximco Pharmaceuticals Ltd announced Tuesday that it will begin selling a generic Merck antiviral medication for COVID-19 after receiving an emergency authorization from the national regulators.

Merck’s drug molnupiravir is currently under review in Europe and the United States, but it was approved last week for use in Britain.

Beximco indicated that the generic version would be launched first in Bangladesh, where it is more accessible. Exports will then be considered depending on global regulatory approvals.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]